Agentix Corp. (AGTX) Financial Statements (2026 and earlier)

Company Profile

Business Address 32932 PACIFIC COAST HIGHWAY
DANA POINT, CA 92629
State of Incorp. NV
Fiscal Year End March 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
Q3
9/30/2025
Q2
6/30/2025
Q1
3/31/2025
Q4
12/31/2024
Q3
9/30/2024
Q2
6/30/2024
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6     
Cash and cash equivalent6     
Prepaid expense    146164158
Other undisclosed current assets  4100869
Total current assets:64100154170167
Noncurrent Assets
TOTAL ASSETS:64100154170167
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8217851,0291,1161,1661,105
Accounts payable7127009691,0671,1281,070
Accrued liabilities1108460483835
Other undisclosed current liabilities2,6022,4922,1751,9551,8411,788
Total current liabilities:3,4243,2763,2053,0713,0072,893
Noncurrent Liabilities
Total liabilities:3,4243,2763,2053,0713,0072,893
Equity
Equity, attributable to parent, including:(3,418)(3,272)(3,104)(2,917)(2,837)(2,726)
Preferred stock     40 
Common stock404040405440
Common stock, value, subscriptions      54
Additional paid in capital3,2883,2883,2883,2883,2883,288
Accumulated other comprehensive income (loss)52543541(23) 
Accumulated deficit(6,851)(6,707)(6,522)(6,340)(6,196)(6,105)
Other undisclosed equity, attributable to parent54545454 (3)
Total equity:(3,418)(3,272)(3,104)(2,917)(2,837)(2,726)
TOTAL LIABILITIES AND EQUITY:64100154170167

Income Statement (P&L) ($ in thousands)

12/31/2025
Q3
9/30/2025
Q2
6/30/2025
Q1
3/31/2025
Q4
12/31/2024
Q3
9/30/2024
Q2
6/30/2024
Q1
Revenues
(Other Income)
  21    
Gross profit:  21    
Operating expenses(123)(200)257(97)(93)(151)
Other undisclosed operating loss  (21)    
Operating income (loss):(123)(200)257(97)(93)(151)
Nonoperating income (expense)(21)151344721
Gain, foreign currency transaction, before tax      
Other nonoperating income (expense) (21)151344721
Other undisclosed income from continuing operations before equity method investments, income taxes   14   
Income (loss) from continuing operations before equity method investments, income taxes:(144)(186)405(50)(91)(151)
Other undisclosed loss from continuing operations before income taxes   (94)  
Income (loss) from continuing operations:(144)(186)405(144)(91)(151)
Other undisclosed net loss   (420)   
Net loss:(144)(186)(15)(144)(91)(151)
Other undisclosed net income attributable to parent   30   
Net income (loss) available to common stockholders, diluted:(144)(186)15(144)(91)(151)

Comprehensive Income ($ in thousands)

12/31/2025
Q3
9/30/2025
Q2
6/30/2025
Q1
3/31/2025
Q4
12/31/2024
Q3
9/30/2024
Q2
6/30/2024
Q1
Net loss:(144)(186)(15)(144)(91)(151)
Other undisclosed comprehensive income   597   
Comprehensive income (loss):(144)(186)582(144)(91)(151)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2)18(1,169)64(20)(15)
Comprehensive loss, net of tax, attributable to parent:(146)(168)(588)(80)(111)(166)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: